Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities.
/PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer...
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
/CNW/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets,...
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with...
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.,...
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical...
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18...
Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.